In vivo relationship between near-infrared spectroscopy-detected lipid-rich plaques and morphological plaque characteristics by optical coherence tomography and intravascular ultrasound: a multimodality intravascular imaging study.


Journal

European heart journal. Cardiovascular Imaging
ISSN: 2047-2412
Titre abrégé: Eur Heart J Cardiovasc Imaging
Pays: England
ID NLM: 101573788

Informations de publication

Date de publication:
22 06 2021
Historique:
received: 28 10 2019
accepted: 09 01 2020
pubmed: 29 1 2020
medline: 6 8 2021
entrez: 29 1 2020
Statut: ppublish

Résumé

We assessed morphological features of near-infrared spectroscopy (NIRS)-detected lipid-rich plaques (LRPs) by using optical coherence tomography (OCT) and intravascular ultrasound (IVUS). IVUS-NIRS and OCT were performed in the two non-infarct-related arteries (non-IRAs) in patients undergoing percutaneous coronary intervention for treatment of an acute coronary syndrome. A lesion was defined as the 4 mm segment with the maximum amount of lipid core burden index (maxLCBI4mm) of each LRP detected by NIRS. We divided the lesions into three groups based on the maxLCBI4mm value: <250, 250-399, and ≥400. OCT analysis and IVUS analysis were performed blinded for NIRS. We measured fibrous cap thickness (FCT) by using a semi-automated method. A total of 104 patients underwent multimodality imaging of 209 non-IRAs. NIRS detected 299 LRPs. Of those, 41% showed a maxLCBI4mm <250, 39% a maxLCBI4mm 251-399, and 19% a maxLCBI4mm ≥400. LRPs with a maxLCBI4mm ≥400, as compared with LRPs with a maxLCBI4mm 250-399 and <250, were more frequently thin-cap fibroatheroma (TCFA) (42.1% vs. 5.1% and 0.8%; P < 0.001) with a smaller minimum FCT (80 μm vs. 110 μm and 120 μm; P < 0.001); a higher IVUS-derived percent atheroma volume (53% vs. 53% and 44%; P < 0.001) and a higher remodelling index (1.08 vs. 1.02 and 1.01; P < 0.001). MaxLCBI4mm correlated with OCT-derived FCT (r = 0.404; P < 0.001) and was the best predictor for TCFA with an optimal cut-off value of 401 (area under the curve = 0.882; P < 0.001). LRPs with increasing maxLCBI4mm exhibit OCT and IVUS features of presumed plaque vulnerability including TCFA morphology, increased plaque burden, and positive remodelling.

Identifiants

pubmed: 31990323
pii: 5716717
doi: 10.1093/ehjci/jez318
doi:

Substances chimiques

Lipids 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

824-834

Informations de copyright

Published on behalf of the European Society of Cardiology. All rights reserved. © The Author(s) 2020. For permissions, please email: journals.permissions@oup.com.

Auteurs

Christian Zanchin (C)

Cardiology Department, Bern University Hospital, University of Bern, 3012 Bern, Switzerland.

Yasushi Ueki (Y)

Cardiology Department, Bern University Hospital, University of Bern, 3012 Bern, Switzerland.

Sylvain Losdat (S)

Department of Social and Preventive Medicine, Clinical Trials Unit, Institute of Social and Preventive Medicine, Bern University Hospital, 3012 Bern, Switzerland.

Gregor Fahrni (G)

Department of Cardiology, University Hospital Basel, 4031 Basel, Switzerland.

Joost Daemen (J)

Department of Cardiology, Erasmus Medical Center, 3015 Rotterdam, the Netherlands.

Anna S Ondracek (AS)

Department of Cardiology, Medical University of Vienna, 1090 Vienna, Austria.

Jonas D Häner (JD)

Cardiology Department, Bern University Hospital, University of Bern, 3012 Bern, Switzerland.

Stefan Stortecky (S)

Cardiology Department, Bern University Hospital, University of Bern, 3012 Bern, Switzerland.

Tatsuhiko Otsuka (T)

Cardiology Department, Bern University Hospital, University of Bern, 3012 Bern, Switzerland.

George C M Siontis (GCM)

Cardiology Department, Bern University Hospital, University of Bern, 3012 Bern, Switzerland.

Fabio Rigamonti (F)

Department of Cardiology, Geneva University Hospital, 1205 Geneva, Switzerland.

Maria Radu (M)

Department of Cardiology, Rigshospitalet, Copenhagen University Hospital, 2100 Copenhagen, Denmark.

David Spirk (D)

Department of Pharmacology, Institute of Pharmacology, University of Bern, 3012 Bern, Switzerland.

Christoph Kaiser (C)

Department of Cardiology, University Hospital Basel, 4031 Basel, Switzerland.

Thomas Engstrom (T)

Department of Cardiology, Rigshospitalet, Copenhagen University Hospital, 2100 Copenhagen, Denmark.

Irene Lang (I)

Department of Cardiology, Medical University of Vienna, 1090 Vienna, Austria.

Konstantinos C Koskinas (KC)

Cardiology Department, Bern University Hospital, University of Bern, 3012 Bern, Switzerland.

Lorenz Räber (L)

Cardiology Department, Bern University Hospital, University of Bern, 3012 Bern, Switzerland.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH